These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23436421)

  • 21. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inhibiting effect of HPV16 E6 small interfering RNA on the growth of human cervical carcinoma xenotransplanted in nude mice].
    Guan LL; Peng ZL; Niu XY
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):894-7. PubMed ID: 18478926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering the mouse genome to model human disease for drug discovery.
    Koentgen F; Suess G; Naf D
    Methods Mol Biol; 2010; 602():55-77. PubMed ID: 20012392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
    Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
    Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs.
    Gu W; Payne E; Sun S; Burgess M; McMillan NA
    Cancer Gene Ther; 2011 Mar; 18(3):219-27. PubMed ID: 21102424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A resource for large-scale RNA-interference-based screens in mammals.
    Paddison PJ; Silva JM; Conklin DS; Schlabach M; Li M; Aruleba S; Balija V; O'Shaughnessy A; Gnoj L; Scobie K; Chang K; Westbrook T; Cleary M; Sachidanandam R; McCombie WR; Elledge SJ; Hannon GJ
    Nature; 2004 Mar; 428(6981):427-31. PubMed ID: 15042091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.
    Hogrefe RI; Lebedev AV; Zon G; Pirollo KF; Rait A; Zhou Q; Yu W; Chang EH
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(8):889-907. PubMed ID: 16901821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNAi and high-content screening in target identification and validation.
    Haney SA
    IDrugs; 2005 Dec; 8(12):997-1001. PubMed ID: 16320133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of intratracheal instillation of lung tumour cells in mice using single photon emission computed tomography/computed tomography imaging.
    Buckle T; van Leeuwen FW
    Lab Anim; 2010 Jan; 44(1):40-5. PubMed ID: 19854758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The silent treatment: siRNAs as small molecule drugs.
    Dykxhoorn DM; Palliser D; Lieberman J
    Gene Ther; 2006 Mar; 13(6):541-52. PubMed ID: 16397510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Main approaches to target discovery and validation.
    Sioud M
    Methods Mol Biol; 2007; 360():1-12. PubMed ID: 17172722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo imaging of oligonucleotide delivery.
    Takeshita F; Takahashi RU; Onodera J; Ochiya T
    Methods Mol Biol; 2012; 872():243-53. PubMed ID: 22700416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
    Lohmann S; Herold A; Bergauer T; Belousov A; Betzl G; Demario M; Dietrich M; Luistro L; Poignée-Heger M; Schostack K; Simcox M; Walch H; Yin X; Zhong H; Weisser M
    Methods; 2013 Jan; 59(1):10-9. PubMed ID: 22796720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.